Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Z Best Place to Talk Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Ron McKinnon who wrote (20740)	9/16/1999 9:29:00 PM
From: Larry S.	Read Replies (2) \| Respond to of 53068

<<Larry, I'm p*ssed that you did not make me go back into AIRO today in the 16's; it's all your fault >> You can lead a horse to water but you can't make 'em drink. I bot at 16 1/2, sold at 20 3/4, bot back at 18 3/4. plus bot at 17 1/2, sold at 18 7/8 in other account. love that stock. still holding 14 1/2s and 15s. Larry

To: Ron McKinnon who wrote (20740)	9/19/1999 3:18:00 PM
From: DanZ	Read Replies (2) \| Respond to of 53068

GUMM, NITE, VPHM. Ron, Thanks for your views on GUMM. I obtained a copy of the abstract that Dr. Hensley, co-developer of Zicam, presented at a medical conference in Corfu in April. This is the first time that the abstract has been released publicly outside the medical conference, and the results of the study, as described in the limited abstract, look quite conclusive. If the study is accepted by the New England Journal of Medicine, there's no telling how high the stock will trade. VPHM nearly quadrupled in the week that it's news came out, and Pleconaril isn't even as effective as Zicam, nor did its stock have a large short interest like GUMM. GumTech might also be close to announcing a joint venture to manufacture and distribute nicotine gum, and that should also have a big impact on the stock. I welcome both positive and negative feedback from everyone on the abstract. beta.siliconinvestor.com beta.siliconinvestor.com NITE doesn't look very good to me. The stock closed below its lower daily bollinger band last Friday and also closed below recent lows on the weekly chart. If 24 doesn't hold, I think it has risk to 18. Gads, I hope that doesn't happen. The daily money flow was very bad last week, and accelerated each day as the stock closed lower. I don't like the look of the chart, although it might be a great buy based on fundamentals. FWIW, VPHM has shown distribution between 28 and 29 on the daily chart. If it doesn't get through there soon, I wouldn't hold it. It's a dangerous short, but might make a good short term trade. Dan